Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study

Background: Up to 20% of patients with chronic immune-mediated sensorimotor neuropathies (CIN) do not respond adequately to first-line therapies. However, studies on further treatment are scarce. Methods: We analyzed retrospectively 200 CIN patients regarding disease characteristics and response to...

Full description

Bibliographic Details
Main Authors:	Jeremias Motte, Anna Lena Fisse, Nuray Köse, Thomas Grüter, Hannah Mork, Diamantis Athanasopoulos, Miriam Fels, Susanne Otto, Ines Siglienti, Christiane Schneider-Gold, Kerstin Hellwig, Min-Suk Yoon, Ralf Gold, Kalliopi Pitarokoili
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-03-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756286421999631

Similar Items

Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients
by: Diamantis Athanasopoulos, et al.
Published: (2021-05-01)

Nerve Ultrasound Distinguishes Non-Inflammatory Axonal Polyneuropathy From Inflammatory Polyneuropathy With Secondary Axonal Damage
by: Jil Brünger, et al.
Published: (2022-01-01)

Nerve Echogenicity in Polyneuropathies of Various Etiologies—Results of a Retrospective Semi-Automatic Analysis of High-Resolution Ultrasound Images
by: Anke Erdmann, et al.
Published: (2022-05-01)

Longitudinal study on nerve ultrasound and corneal confocal microscopy in NF155 paranodopathy
by: Diamantis Athanasopoulos, et al.
Published: (2020-06-01)

Treatment of an acute motor and sensory axonal neuropathy with propionate in a 33-year-old male
by: Min-Suk Yoon, et al.
Published: (2018-11-01)

Capsaicin-enriched diet ameliorates autoimmune neuritis in rats
by: Jeremias Motte, et al.
Published: (2018-04-01)

Quantitative magnetic resonance neurography in chronic inflammatory demyelinating polyradiculoneuropathy: A longitudinal study over 6 years
by: Fabian Preisner, et al.
Published: (2024-03-01)

Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection
by: Björn Ambrosius, et al.
Published: (2017-04-01)

Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis
by: Kalliopi Pitarokoili, et al.
Published: (2019-09-01)

Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy
by: Jeremias Motte, et al.
Published: (2021-07-01)

Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct anti-oxidative effects on Schwann cells
by: Kalliopi Pitarokoili, et al.
Published: (2019-03-01)

Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells
by: Thomas Grüter, et al.
Published: (2020-05-01)

Comparative analysis of albumin quotient and total CSF protein in immune-mediated neuropathies: a multicenter study on diagnostic implications
by: Tabea Seeliger, et al.
Published: (2024-01-01)

Correlates of polyneuropathy in Parkinson’s disease
by: Eva Kühn, et al.
Published: (2020-10-01)

Ventricular tachycardia during basilar-type migraine attack
by: Kalliopi Pitarokoili, et al.
Published: (2013-01-01)

Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
by: Arash Maleki, et al.
Published: (2022-11-01)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
by: Shota Yamamoto, et al.
Published: (2021-01-01)

Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients
by: Fang Fang, et al.
Published: (2024-01-01)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
by: Christiane Schneider-Gold, et al.
Published: (2017-10-01)

Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
by: Rafiye Ciftciler, et al.
Published: (2020-05-01)

The protective effects of lafutidine for bortezomib induced peripheral neuropathy
by: Tsukaguchi M, et al.
Published: (2013-07-01)

Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain
by: W. Iris Zhi MD, PhD, et al.
Published: (2018-12-01)

Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal Protection.
by: Kalliopi Pitarokoili, et al.
Published: (2015-01-01)

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020-10-01)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
by: Frank B. Cortazar, et al.
Published: (2018-03-01)

Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy
by: Mohit Dogra, et al.
Published: (2018-01-01)

A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab
by: Chaoyuan Kuang, et al.
Published: (2020-10-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
by: Edvan De Queiroz Crusoe, et al.
Published: (2020-04-01)

Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats
by: Shota Yamamoto, et al.
Published: (2015-09-01)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
by: Jeter Ashley, et al.
Published: (2012-08-01)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
by: Xiaowei Xu, et al.
Published: (2013-12-01)

Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01)

Bortezomib-induced neuropathy is in part mediated by the sensitization of TRPV1 channels
by: Jared M. Sprague, et al.
Published: (2023-12-01)

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
by: Xiang Zhou, et al.
Published: (2023-05-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
by: Jones, R, et al.
Published: (2009)

P148 Comparison of cyclophosphamide and rituximab in the treatment of severe systemic lupus erythematosus
by: László Kovács, et al.
Published: (2024-03-01)